

Supporting information

Ligand Free FeSn₂ Alloy Nanoparticles for Safe T2-weighted MR Imaging of *In vivo* Lung Tumors

Suresh Thangudu^{a,b,#}, Wei-Che Lin^{b,#}, Chin-Lai Lee^b, , Min-Chiao Liao^c, Chun-Chieh Yu^d, Yu-Ming Wang^{c*}, Chia-Hao Su^{a,b,c,e*}

a. Center for General Education, Chang Gung University, Taoyuan, 333, Taiwan.

b. Department of diagnostic radiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

c. Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

d. Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

e. Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.

*Correspondence: chiralsu@gmail.com (CH Su); scorpion@cgmh.org.tw (YM Wang)

Authors contributed equally to this work




Figure S1. Energy Dispersive X-Ray Analysis (EDX) elemental analysis of FeSn₂ alloy NPs.

Intensity Distribution




Figure S2. DLS spectra of FeSn₂ alloy NPs (PDI value 0.180).




Figure S3. (A) and (B) UV-visible absorption spectra and corresponding optical images of FeSn₂ alloy NPs aqueous solutions at different incubation times.




Figure S4. Transversal relaxation time ($1/T_2$, s^{-1}) against the concentration of Fe in $FeSn_2$ alloy NPs.




Figure S5. Cytotoxicity evaluation of different concentrations of $FeSn_2$ alloy NPs with the CCK-8 assay.




Figure S6. *In vivo* MR imaging of lung tumor mice models (n=3) on FeSn₂ alloy NPs (pre, post-injection of NPs-immediately, 1 h, 3 h, 5 h).